PDF(Pubmed)
Abstract：
The literature about the association of branched short-chain fatty acids (BCFAs) and irritable bowel syndrome (IBS) is limited. BCFAs, the bacterial products of the catabolism of branched-chain amino acids, are proposed as markers for colonic protein fermentation. IBS is a gastrointestinal disorder characterized by low-grade inflammation and intestinal dysbiosis. The low-FODMAP diet (LFD) has increasingly been applied as first-line therapy for managing IBS symptoms, although it decreases the production of short-chain fatty acids (SCFA), well known for their anti-inflammatory action. In parallel, high protein consumption increases BCFAs. Protein fermentation alters the colonic microbiome through nitrogenous metabolites production, known for their detrimental effects on the intestinal barrier promoting inflammation. Purpose: This review aims to explore the role of BCFAs on gut inflammation in patients with IBS and the impact of LFD in BCFAs production. Methods: A literature search was carried out using a combination of terms in scientific databases. Results: The included studies have contradictory findings about how BCFAs affect the intestinal health of IBS patients. Conclusions: Although evidence suggests that BCFAs may play a protective role in gut inflammation, other metabolites of protein fermentation are associated with gut inflammation. Further research is needed in order to clarify how diet protein composition and, consequently, the BCFAs are implicated in IBS pathogenesis or in symptoms management with LFD+.
摘要：
关于支链短链脂肪酸（BCFA）与肠易激综合征（IBS）的关联的文献有限。BCFAs,支链氨基酸分解代谢的细菌产物，被提议作为结肠蛋白发酵的标志物。IBS是一种以低度炎症和肠道生态失调为特征的胃肠道疾病。低FODMAP饮食（LFD）已越来越多地用作治疗IBS症状的一线治疗。虽然它减少了短链脂肪酸（SCFA）的产生，以其抗炎作用而闻名。并行,高蛋白消耗会增加BCFAs。蛋白质发酵通过含氮代谢产物的产生改变了结肠微生物组，以其对促进肠道屏障炎症的有害作用而闻名。目的：本综述旨在探讨BCFAs在IBS患者肠道炎症中的作用以及LFD对BCFAs产生的影响。方法：使用科学数据库中的术语组合进行文献检索。结果：纳入的研究对BCFAs如何影响IBS患者的肠道健康有矛盾的发现。结论：尽管有证据表明BCFAs可能在肠道炎症中起保护作用，蛋白质发酵的其他代谢产物与肠道炎症有关。需要进一步的研究，以澄清饮食蛋白质成分和，因此,BCFAs与IBS发病机制或LFD+的症状管理有关。
